triumph 1 trial retatrutide Retatrutide produces up to 30.3% weight loss in Phase 3 trial

Eli Lilly and Co. announced on Thursday that its experimental obesity drug retatrutide achieved up to 28.3 percent body-weight reduction over 80 weeks in the pivotal Phase 3 TRIUMPH-1 trial — a

27.83

★★★★☆4.8 (126)

Retatrutide triumph 1 results 2026

23.15

★★★★★4.9 (98)

The numbers from Lilly's Phase 3 retatrutide trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user

24.22

★★★★★5.0 (157)

First Retatrutide phase 3 data, a Triumph of Science!

28.96

★★★★★4.7 (84)

Retatrutide just delivered the first top-line Phase 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇

25.95

★★★★★4.9 (203)

Retatrutide Explained: Mechanism, Phase 3 TRIUMPH-1 Results, Safety, and Future Potential – C2 Peptides

25.13

★★★★★5.0 (176)

Do not obsess over Retatrutide. It is not risk-free. Retatrutide acts on three separate pathways—GLP-1, GIP, and glucagon receptors—creating profound effects on appetite, energy balance, and body weight. The problem? Most people

28.80

★★★★★4.8 (132)